BAT and PMI Collaborate to Produce Cigarettes in Switzerland

BATPMI by 2FIRSTS.ai
Dec.04.2023
BAT and PMI Collaborate to Produce Cigarettes in Switzerland
Swiss media Le Temps reports that British American Tobacco's Swiss subsidiary has reached a production agreement with Philip Morris International.

Swiss media outlet Le Temps reported on December 1st that the Swiss subsidiary of British American Tobacco (BAT) has revealed a collaboration agreement with Philip Morris International (PMI). According to the agreement, PMI will produce cigarettes for BAT at their factory located in the western Swiss city of Neuchâtel.

 

In its statement, BAT pointed out that this agreement is specifically targeted towards the domestic market in Switzerland. Reports suggest that due to insufficient production capacity at BAT's factories in Switzerland to meet market demands, the company has opted to collaborate with a rival factory. This is a common practice in the world of multinational corporations.

 

British American Tobacco (BAT) has announced that only a portion of its production in Neuchâtel will be dedicated to the Swiss market, while the remaining output, as well as previously exported goods, will be handled by other factories within the BAT Group. As part of the agreement between the two tobacco giants, six new positions will be added to the Boncourt factory (BAT's Switzerland-based facility).

 

This summer, British American Tobacco Switzerland announced that they would not completely exit Boncourt's operations, but would continue to retain warehouses and a shipping department there, providing approximately 15 jobs. The company's headquarters will also remain in Jura canton. As of December 14th, 2022, when the closure of the factory was announced, it employed a total of 220 staff members.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Dutch Ministry of Finance reports: Dutch tobacco tax revenue stagnates, mainly due to cross-border consumption shift
Dutch Ministry of Finance reports: Dutch tobacco tax revenue stagnates, mainly due to cross-border consumption shift
A report released by the Dutch Ministry of Finance indicates that tobacco tax increases have failed to boost fiscal revenue. The previously projected €7 million in revenue from a 5 cent per pack tax increase has now fallen to zero, primarily due to cross-border cigarette purchases. The current excise tax on cigarettes is €7.81 per pack, with no further increases planned. Tobacco tax revenue is projected to reach €2.5 billion in both 2025 and 2026.
Sep.24 by 2FIRSTS.ai
Ukrainian Researchers Estimate E-Cigarette Black Market at 90%, Warn of About $180 Million Budget Hit in 2025
Ukrainian Researchers Estimate E-Cigarette Black Market at 90%, Warn of About $180 Million Budget Hit in 2025
Ukrainian researchers estimate that the illicit e-cigarette market makes up about 93% of total sales. Based on the National Bank of Ukraine’s exchange rate, if the black market remains at its current size, Ukraine’s state and local budgets could lose roughly $180 million in revenue in 2025.
Oct.16 by 2FIRSTS.ai
Teen Nicotine Use Surges in Pakistan as Flavoured Vapes Spread Rapidly
Teen Nicotine Use Surges in Pakistan as Flavoured Vapes Spread Rapidly
Pakistan is experiencing a sharp rise in nicotine use among teenagers, driven by widespread availability of flavoured vapes and e-cigarettes. Cheap, sweet-flavoured devices are easily accessible in major cities, and weak enforcement of age limits has enabled young users to adopt vaping at alarming rates. Activists warn that industry marketing falsely portrays e-cigarettes as “safer,” putting youth at risk of long-term addiction and serious health effects.
Nov.14 by 2FIRSTS.ai
STMA to Hold Hearing on License Leasing Case in Shenzhen
STMA to Hold Hearing on License Leasing Case in Shenzhen
The State Tobacco Monopoly Administration (STMA) announced a public hearing will be held on Nov. 11 at 9 a.m. in Bao’an District, Shenzhen, regarding Shenzhen Biaogan Zhizao Technology Co., Ltd. accused of leasing its tobacco retail license.
Oct.31 by 2FIRSTS.ai
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai
U.S. Company TPB Q3 Earnings: Nicotine Pouch Sales Surge 628% YoY, First U.S. Production Line Planned
U.S. Company TPB Q3 Earnings: Nicotine Pouch Sales Surge 628% YoY, First U.S. Production Line Planned
Turning Point Brands (NYSE: TPB) released its financial results for the third quarter of 2025, reporting strong revenue and profit growth driven by surging Modern Oral (nicotine pouch) sales. The company announced plans to establish its first U.S.-based white pouch production line in 2026, marking a key step toward manufacturing localization.
Nov.06 by 2FIRSTS.ai